Last updated: February 15, 2026
Overview
NDC 70677-0122 is the drug Siponimod, marketed under the brand name Mayzent. It is approved for the treatment of relapsing forms of multiple sclerosis (MS), specifically active secondary progressive MS (SPMS). The drug belongs to the sphingosine-1-phosphate (S1P) receptor modulator class. Industry and market data focus on its commercial potential, patient adoption, competitive landscape, and pricing dynamics.
Market Landscape
1. Disease Burden and Patient Population
- Multiple sclerosis affects over 2.8 million people worldwide, with approximately 1 million in the U.S. [1].
- Active secondary progressive MS (SPMS) accounts for an estimated 40-50% of MS cases in the US.
- The eligible patient base for Siponimod is estimated at 200,000–250,000 in the U.S., considering diagnosed cases and treatment eligibility.
2. Competitive Position
- Approved in 2019, Siponimod competes primarily with other oral S1P receptor modulators like Fingolimod (Gilenya), Ozanimod (Zeposia), and Ponesimod (Ponvory).
- Its differentiation lies in indications for active SPMS, an unmet need area.
- The competitive landscape includes biologics and infusion therapies, but oral agents maintain preference for convenience.
3. Market Penetration and Trends
- As of 2023, Mayzent has experienced steady growth, with estimated U.S. sales reaching approximately $600 million annually [2].
- Adoption rates vary from 15-20% of eligible MS patients, driven by physician familiarity, side-effect profiles, and formulary access.
- The rise of biosimilar and generic competition for some classes influences future market dynamics.
Price Projections
1. Current Pricing (2023)
- The average wholesale price (AWP) is approximately $83,000–$85,000 per year per patient, based on Medicare reimbursement data and commercial pricing [3].
- The mean net price after negotiations and rebates is estimated at $65,000–$70,000 annually.
2. Factors Influencing Price Trends
- Patent exclusivity and regulatory protections support stable pricing for the next several years.
- Entry of biosimilars or generics would pressure prices downward; however, for Siponimod, no generics are currently available.
- Pricing adjustments may occur due to reimbursement policy updates, utilization shifts, or approval of newer therapies.
3. Future Pricing Outlook (Next 3–5 Years)
| Scenario |
Price Range (per patient/year) |
Assumptions |
| Stable |
$65,000 – $70,000 |
No significant biosimilar/generic impact; market stability persists. |
| Moderate decline |
$55,000 – $60,000 |
Entry of biosimilars or additional generics; increased competition. |
| Significant decline |
<$50,000 |
Widespread biosimilar entry; rapid adoption of alternative therapies. |
4. Revenue Projections
- Assuming an incremental adoption reaching 25-30% of the eligible patient base ($200,000 to 250,000), potential gross revenue ranges from $300 million to $525 million annually.
- Accounting for discounts, rebates, and formulary restrictions, net revenue could fall between $200 million and $350 million annually.
Regulatory and Policy Impact
- Price controls, reimbursement policies, and Medicare Part D negotiations significantly influence net pricing.
- The Inflation Reduction Act and price negotiation provisions for certain biologics may eventually impact prices.
- The FDA’s approval of new indications might expand the market, supporting sustained or increased pricing.
Key Takeaways
- The U.S. market for Siponimod is valued at approximately $600 million annually, with growth driven by its niche indication.
- Price per patient remains high, around $65,000–$70,000 net, with potential declines contingent on biosimilar/generic entry.
- Market share will depend on physician adoption, patient access, and competitive dynamics.
- Future revenues are sensitive to regulatory changes, emerging competitors, and shifts in treatment paradigms for MS.
FAQs
Q1: What are the primary competitors to Siponimod?
Fingolimod (Gilenya), Ozanimod (Zeposia), and Ponesimod (Ponvory) are the main oral S1P receptor modulators competing in MS treatment, with Ponesimod being the newest, approved in 2021.
Q2: How does pricing of Siponimod compare internationally?
International prices are generally lower due to price regulation policies, with European prices often 30-50% lower than U.S. prices. Reimbursement and pricing vary significantly between countries.
Q3: Will biosimilar or generic versions significantly impact Siponimod's price?
Currently, no biosimilars or generics exist for Siponimod. The development and approval of biosimilar drugs could reduce prices by 20-40% over the next 3–5 years if market entry occurs.
Q4: How does the approval for specific MS subtypes influence pricing?
Niche approval for active SPMS limits the patient pool, which supports premium pricing due to limited competition in this segment.
Q5: What factors could alter market size and pricing in the near future?
Introducing new treatments for MS, regulatory changes, patent challenges, and shifts in prescribing behaviors could significantly modify market size and pricing.
Citations
[1] Multiple Sclerosis International Federation. "Atlas of MS 2022."
[2] IQVIA. "U.S. MS market sales data 2022."
[3] Medicare Part D Drug List and Commercial Pricing Data, 2023.
